ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit
Werte in diesem Artikel
BENSALEM, Pa., Sept. 5, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX).
Class Period: March 17, 2022 – June 20, 2023
Lead Plaintiff Deadline:September 29, 2023
Investors suffering losses on their Aldeyra investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) the ADX-2191 NDA did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191's effectiveness; (2) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (3) accordingly, the Company had overstated ADX-2191's clinical and/or commercial prospects; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
View original content:https://www.prnewswire.com/news-releases/aldx-investors-have-opportunity-to-lead-aldeyra-therapeutics-inc-securities-fraud-lawsuit-301918094.html
SOURCE Law Offices of Howard G. Smith
Ausgewählte Hebelprodukte auf Aldeyra Therapeutics
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Aldeyra Therapeutics
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Aldeyra Therapeutics Aktie News
Aldeyra Therapeutics Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Aldeyra Therapeutics nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 26.09.18 | Aldexa Therapeutics Overweight | Cantor Fitzgerald | |
| 26.01.18 | Aldexa Therapeutics Buy | Seaport Global Securities | |
| 26.09.16 | Aldexa Therapeutics Buy | H.C. Wainwright & Co. | |
| 01.07.16 | Aldexa Therapeutics Buy | Stifel, Nicolaus & Co., Inc. | |
| 01.07.15 | Aldexa Therapeutics Buy | Canaccord Adams |